- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
New England Research & Management Inc. Acquires 17,400 Shares in Incyte Corporation
The investment firm added a new stake in the biopharmaceutical company during the fourth quarter.
Mar. 22, 2026 at 10:10am
Got story updates? Submit your updates here. ›
New England Research & Management Inc. purchased a new stake of 17,400 shares in Incyte Corporation (NASDAQ:INCY) during the fourth quarter, according to a report. The shares were valued at approximately $1.72 million. Other institutional investors and hedge funds also recently made changes to their Incyte holdings.
Why it matters
Incyte is a prominent biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases. The acquisition of a new stake by New England Research & Management Inc. signals continued institutional investor interest in the company's pipeline and future growth potential.
The details
New England Research & Management Inc. purchased 17,400 shares of Incyte Corporation in the fourth quarter. The shares were valued at around $1.72 million. Other institutional investors and hedge funds have also been adjusting their Incyte holdings, with some adding to their positions and others reducing their stakes.
- The new stake was purchased in the fourth quarter of 2025.
The players
New England Research & Management Inc.
An investment firm that acquired a new stake in Incyte Corporation during the fourth quarter.
Incyte Corporation
A biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases.
The takeaway
The acquisition of a new stake in Incyte Corporation by New England Research & Management Inc. suggests continued institutional investor interest in the biopharmaceutical company's pipeline and growth potential.
